Fig. 4: PF-477736 treatment is proof-of-concept inhibitor of LIMD1-deficient lung cancers.
From: Targeted therapy for LIMD1-deficient non-small cell lung cancer subtypes
A Immunoblot of isogenic LIMD1−/− small airway epithelial cells (SAEC) and control. B Dose–response of PF-477736 in isogenic LIMD1−/− SAEC. Cells were treated twice prior to measuring cell viability and calculating surviving fraction (n = 3). C Immunoblot of LIMD1 in a panel of lung adenocarcinoma cell lines (representative blot from n = 3). D Pearson’s correlation coefficient between LIMD1 protein expression and surviving fraction of indicated cell line after treatment with 1 µM PF-477736. E Relative tumour growth of subcutaneous A549 isogenic xenografts implanted into the flank of NOD/SCID mice. Mice were treated twice on indicated days with vehicle or PF-477736 (7.5 mg/kg per dose) (n = 10 per group). F, G Immunohistochemical staining and scoring of Ki67 (F) and cleaved caspase-3 (G) in mouse xenograft tumours (n = 10 per group, two-way ANOVA).
